Trevi Therapeutics Inc
TRVIHealthcare|Biotechnology|USA
$17.84
-0.56 (-3.02%)
Tangible Book
$1.34
Earnings Power
$1.16
About
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Stock Price
+178.4%(1Y)
Pipeline Summary
17 total trials6
Phase 1
9
Phase 2
6
Phase 3
0
Phase 4
Completed: 13Recruiting: 4
Active Trials (4)
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911Idiopathic Pulmonary Fibrosis
Phase 3Recruiting
Enrollment: 306 participants
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
NCT07487740Healthy Participants
Phase 1Recruiting
Enrollment: 60 participants
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
NCT07671924Refractory Chronic Cough
Phase 2Recruiting
Enrollment: 100 participants
NAL ER IPF Respiratory Function and Safety Study
NCT07036029Idiopathic Pulmonary Fibrosis
Phase 1Recruiting
Enrollment: 10 participants
BioScore
5.1/10
Watchlist
Ownership
Recent Insider Trades
SCIASCIA THOMASSELL
2025-03-252,631 shares @ $6.6
GOOD JENNIFER LSELL
2025-03-215,263 shares @ $6.58
Simon FarrellSELL
2025-03-1081,313 shares @ $6.75
GOOD JENNIFER LSELL
2024-09-096,059 shares @ $3.03
GOOD JENNIFER LSELL
2024-09-0555,121 shares @ $3.09
Data last updated: Jul 13, 2026, 12:42 PM